


FIG. 1


Binding of PD-L1xIL-15 ISA
to CD14+ monocytes
PD-L1
PD-L1
Monocyte
Binding of NK and CD8 T
cells to PD-L1xIL-15 ISA
NK cell
Cytotoxic
CD8 T cell
PD-L1
PD-L1
Monocyte
Activation and proliferation
of NK and CD8 T cells
PD-L1
PD-L1
Monocyte

FIG. 2


3C5 IgM+J*RI
HSA-RI
KD-RI
153 IgM+J*RI
3C5 IgM+JH
Ki67+ (% CD8 T cells)
50
40
30
20
10
0
0.001
0.01
0.1
1
10
100
Compound nM

FIG. 3


CD8 T cells
T regulatory CD4
CD4 T cells
Ki67+ (% cells)
100
80
60
40
20
0
0.01
0.1
1
10
100
Antibody (nM)

FIG. 4


J*RI-N1D
J*RI-N4D
J*RI-D61N
J*RI-N72D
J*RI-D30N
J*RI-E64Q
J*RI
J*RI-N65D
J*RI-Q108E
J*RI-D8N
JH
NK cells proliferation
Ki67+ (% NK cells)
0
20
40
60
80
$10^0$
$10^1$
$10^2$
$10^3$
$10^4$
$10^5$
Antibody (pM)

FIG. 5B


CD8+ T cells proliferation
Ki67+ (% CD8 T cells)
0
20
40
60
$10^1$
$10^2$
$10^3$
$10^4$
$10^5$
Antibody (pM)

FIG. 5A

FIG. 5C


CD8+ T cells proliferation
Ki67+ (% CD8 T cells)
Antibody (pM)
50X

FIG. 5D


NK cells proliferation
Ki67+ (% NK cells)
Antibody (pM)
100X
J*RI-N4D-N65D
J*RI
J*RI-N1D-N65D
J*RI-D30N-E64Q-N65D
J*RI-9X
JH


3C5 IgM+J*RI
HSA-RI
153 IgM+J*RI
KD-RI
3C5 IgM+JH
% of CD8 T cells expressing
100
80
60
40
20
0
GITR
OX-40
Ki-67

FIG. 6


3C5 IgM+J*RI
GITR IgM+J*RI #12
GITR IgM+J*RI #23
GITR IgM+J*RI #14
3C5 IgM+JH
5-10X
Ki67+ (% CD8 T cells)
Antibody (nM)
0
20
40
60
80
100
0.1
1
10
100

FIG. 7

FIG. 8A


CD8+ T cells proliferation donor 230
Ki67+ (% CD8 T cells)
Antibody (nM)
3C5 + SJ*
3C5 + SJ*RI
3C5 + J*RI
3C5 + J*

FIG. 8B


CD8+ T cells proliferation donor 403
Ki67+ (% CD8 T cells)
Antibody (nM)
3C5 + SJ*RI
3C5 + SJ*
3C5 + J*RI
3C5 + J*
Legend

FIG. 8D


NK cells proliferation donor 403
Ki67+ (% NK cells)
100
80
60
40
20
0
0.0001
0.001
0.01
0.1
1
10
100
Antibody (nM)
3C5 + J*RI
3C5 + SJ*RI
3C5 + SJ*
3C5 + J*

FIG. 8C


NK cells proliferation donor 230
Ki67+ (% NK cells)
100
80
60
40
20
0
0.0001
0.001
0.01
0.1
1
10
100
Antibody (nM)
3C5 + J*RI
3C5 + SJ*RI
3C5 + SJ*
3C5 + J*




FIG. 9A

FIG. 9B

FIG. 9C

FIG. 9D


FIG. 10A
Re-challenge with CT26
Tumor volume mm³ ± SEM
Days post inoculation
Naive n=15
Treated n=19
FIG. 10B
Day 38
****
Tumor volume mm³
naive
treated
FIG. 10C
Naive
Tumor volume mm³
Days post inoculation
FIG. 10D
Treated mice
Tumor volume mm³ ± SEM
Days post inoculation

PCT/US20/46379 13 October 2020 (13.10.2020)




CD8+ T cells proliferation
J*RI N1D/N2D/N3D/N4D
J*RI N4D
J*RI N3D
J*RI N2D
J*RI N1D
J*RI
Ki67+ (% CD8 T cells)
0
20
40
60
80
0.01
0.1
1
10
100
Antibody (nM)

FIG. 12




FIG. 13B




FIG. 13A




FIG. 14A




FIG. 14B




FIG. 14C




FIG. 14D




FIG. 14E




FIG. 14F


FIG. 15A
PBMC (E:T 1:1)
% Specific Killing ± SEM
Ab conc (nM)
FIG. 15B
NK Cells (E:T 1:1)
% Specific Killing ± SEM
Ab conc (nM)
FIG. 15C
CD8 T Cells (E:T 1:1)
% Specific Killing ± SEM
Ab conc (nM)
m3c5-J*RI
3C5 IgM J*




FIG. 16